32 ug/ml and ≥64 ug/m were considered susceptible, susceptible dose-dependent (S-DD) and resistant to fluconazole, respectively.
Results
Among 3,056 clinical isolates, 2,170 (71.0%) isolates were identified as C. albicans, followed by C. glabrata (547, 17.9%), C. tropicalis (155, 5.1%), C. krusei (114, 3.7%), C. parapsilosis (17, 0.6%) and other Candida species (53, 1.7%). Overall, 87.7% Candida isolates were susceptible to fluconazole. The resistance rate of C. albicans, C. glabrata, C. tropicalis and C. krusei was 4.3%, 5.7%, 7.1% and 100%, respectively.
The Candida spp. isolates were collected from various clinical specimen types, including blood, urine, ascites, faecal, respiratory tract and vaginal tract specimens as shown in Table 1 , C. albicans constituted more than 65.0% of isolates from the respiratory (77.0%) and vaginal (67.0%) tract specimens. C. glabrata constituted 40.9% and 33.0% of all Candida spp. from blood and urine, respectively. C. tropicalis accounted for 12.7% of all urinary tract isolates of Candida but was less common (<7%) as an agent of candidiasis among other specimen types. The rate of fluconazole susceptibility was 91.1%, 78.6%, 87.3%, 85.3%, 90.9% for isolates from the respiratory, vaginal, urinary, digestive tract and blood, respectively.
The clinical services in this study included the intensive care unit (ICU), transplant unit, medical, surgical, haematology, oncology, urology, dermatology, burn and paediatric services. As shown in Table 2 , C. albicans mainly isolated from the patient of medical services and outpatients. Non-albicans species accounted for 62.6%, 56.3%, 78.3% of the isolates from the ICU, organ transplant and burn patients, respectively. The fluconazole-resistance rate was 6.7%, 12.0%, 4.8%, 3.1%, 7.0%, 9.3%, 14.1%, 8.3%, 30.4% and 6.7% for isolates from the medical service, outpatients, oncology service, surgical patients, ICU, the haematology service, molysmology service, urology service, burn patient and transplant service.
Discussion
In consistent with other reports, [3] C. albicans was found to be the predominant pathogen in this study. However, it is noteworthy that the distribution of Candida spp. varied among different specimen types and different clinical services. In the present study, C. albicans was the species most commonly isolated from the respiratory, vaginal and digestive specimens, but non-albicans species represented 68.2% and 53.8% of isolates from blood and urinary tract. Similarly, although C. albicans was still the most prevalent species in most of the clinical services, the non-albicans species were the dominant pathogens isolated from the ICU (62.6%), organ transplant (56.3%) and burn patients (78.3%). The increased prevalence of non-albicans Candida species causing invasive candidasis has been widely reported in many studies [5] [6] [7] and may have a profound effect on future clinical outcomes because some non-albicans Candida species have been correlated with higher virulence and mortality than C. albicans. [8] Our data indicated that the activity of fluconazole against Candida species remains high. However, the susceptibility of Candida spp. from different specimens and clinical services varied. The resistance rates of isolates from the different clinical services varied from 0.0% to 30.4%. Notably, the resistance rate for isolates from the vagina, burn patients, molysmology patients and outpatients were very high. Previous investigators have reported that fluconazole resistance in vaginal C. albicans isolates is rare. [9, 10] However, in our survey, 14.6% of the C. albicans strains displayed decreased susceptibility to fluconazole. The high resistance rate in vaginal C. albicans isolates may be associated with repeated exposure to antifungal agents. Meanwhile, in this study, the percentage of non-albicans vaginitis (31.8%) was higher than in previous reports, [10, 11] and these species appeared to have high resistance to fluconazole.
In conclusion, the Candida spp. distribution and fluconazole susceptibility varied among the various 
